84403-70-3

Basic information

• Product Name: 4-(3-CHLORO-BENZYLOXY)-BENZOIC ACID
• Synonyms: 4-(3-CHLORO-BENZYLOXY)-BENZOIC ACID
• CAS NO: 84403-70-3
• Molecular Formula: C₁₄H₁₁ClO₃
• Molecular Weight: 262.69
• Mol File: 84403-70-3.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 423.4 °C at 760 mmHg
• Flash Point: 209.9 °C
• Appearance: /
• Density: 1.322 g/cm³
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 4-(3-CHLORO-BENZYLOXY)-BENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-CHLORO-BENZYLOXY)-BENZOIC ACID(84403-70-3)
• EPA Substance Registry System: 4-(3-CHLORO-BENZYLOXY)-BENZOIC ACID(84403-70-3)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 84403-70-3(Hazardous Substances Data)

Usage

General Description

4-(3-chloro-benzyloxy)-benzoic acid is a chemical compound with the molecular formula C14H11ClO3. It is a white solid with a molecular weight of 264.69 g/mol. 4-(3-CHLORO-BENZYLOXY)-BENZOIC ACID is a derivative of benzoic acid and contains a benzyl ether group and a 3-chloro substituent on the benzene ring. 4-(3-chloro-benzyloxy)-benzoic acid is commonly used as an intermediate in the synthesis of pharmaceuticals and other organic compounds. It has potential applications in the fields of medicine, agrochemicals, and materials science. Additionally, it is important to handle this compound with care as it requires proper storage and handling procedures due to its potential hazards.

Upstream product

• 766-80-3 1-bromomethyl-3-chlorobenzene 
• 99-96-7 4-hydroxy-benzoic acid 
• 84403-77-0 methyl 4-(3'-chlorobenzyloxy)-benzoate 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 620-20-2 1-Chloro-3-chloromethyl-benzene 

Relevant articles and documents

Discovery of benzamide-hydroxypyridinone hybrids as potent multi-targeting agents for the treatment of Alzheimer's disease

A novel class of benzamide-hydroxypyridinone (HPO) derivatives were innovatively designed, synthesised, and biologically evaluated as potential multitargeting candidates for the treatment of Alzheimer's disease (AD) through pharmacophores-merged approaches based on lead compounds 18d, benzyloxy phenyl analogs, and deferiprone (DFP). These hybrids possessed potent Monoamine oxidase B (MAO-B) inhibition as well as excellent iron chelation, with pFe3+ values ranging from 18.13 to 19.39. Among all the compounds, 8g exhibited the most potent selective MAO-B inhibitor (IC50 = 68.4 nM, SI = 213). Moreover, 8g showed favourable pharmacokinetic properties and had great potential to penetrate the BBB in silico and PAMPA-BBB assay. Molecular modelling showed that 8g could adopt an extended conformation and have more enhanced interactions with MAO-B than 18d. In vitro and in vivo assays demonstrated that 8g remarkably resisted Aβ-induced oxidation and ameliorated cognitive impairment induced by scopolamine. Taken collectively, these results suggest that compound 8g is a potential multifunctional candidate for anti-AD treatment.

Formamide pyridone iron chelating agent derivative with potential multi-target anti-AD activity as well as preparation method and application thereof

The invention provides a formamide pyridone iron chelating agent derivative shown as a formula (I) or a formula (II) which is described in the specification and a preparation method and application thereof. The formamide pyridone iron chelating agent derivative shown in the formula (I) or the formula (II) and the pharmaceutically acceptable salt thereof have the effects of inhibiting monoamine oxidase, chelating metal iron ions, resisting A beta and resisting oxidation activity. The derivative can be used for preparing medicines for resisting Alzheimer's disease, Parkinson's disease or other diseases treated by inhibiting monoamine oxidase, chelating metal iron ions, resisting A beta and resisting oxidation.